Chiesi has a passionate commitment to innovation in terms of both active ingredients and new formulations. In 2018 Chiesi is the 1st Italian pharmaceutical company in Europe for patent deposits. More than 3,754 worldwide patents in the Chiesi portfolio.
In 2018, investment in R&D continued to grow – the expenditure exceeded €381.8 million, equating to €1.05 million per day and 21.6% of Chiesi Group revenues.
Our Research and Development team represents a fundamental asset in our business. It comprises multi-functional business areas (focussing on pipeline projects), which include:
Moreover, research and development functions also support products already on the market through pharmacovigilance and regulatory activities.
Our traditional research and development focus is now complemented by new research areas in rare diseases, biotechnology, gene therapy and transplantation.
UK-CHI-2000007 January 2020